<DOC>
	<DOCNO>NCT01436656</DOCNO>
	<brief_summary>CLGX818X2101 first-time in-human , phase I study establish maximum tolerate dose ( MTD ) and/or recommend phase 2 dose ( RP2D ) daily administer LGX818 ( daily , twice daily and/or every-other-day ) , RAF kinase inhibitor . Patients locally advance metastatic melanoma harbor BRAF V600 mutation ( dose escalation phase expansion phase ) patient metastatic colorectal cancer harbor BRAF V600 mutation ( expansion phase ) enrol . The study consist dose escalation part cohorts patient receive escalate oral dos LGX818 , follow safety dose expansion part patient treat oral dose LGX818 give MTD RP2D .</brief_summary>
	<brief_title>A Phase I Study Oral LGX818 Adult Patients With Advanced Metastatic BRAF Mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>For dose escalation phase : 1 . Histologically confirm diagnosis locally advance metastatic melanoma ( stage IIIB IV per American Joint Committee Cancer [ AJCC ] ) . For dose expansion phase : ( ) Histologically confirm diagnosis locally advance metastatic melanoma ( stage IIIB IV per American Joint Committee Cancer [ AJCC ] ) , ( ii ) confirm diagnosis nonresectable advanced metastatic colorectal cancer ( mCRC ) effective standard therapy exist . 2 . Written documentation BRAF V600E mutation , BRAF V600 mutation . 3 . Evidence measurable disease 1 . Previous therapy MEK inhibitor . 2 . Symptomatic untreated leptomeningeal disease . 3 . Symptomatic untreated brain metastasis.Patients previously treat condition asymptomatic absence corticosteroid therapy allow enroll . Brain metastasis must stable verification image . 4 . Known acute chronic pancreatitis . 5 . Clinically significant cardiac disease 6 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LGX818 7 . Previous concurrent malignancy . Exceptions exclusion criterion include : adequately treat basal cell squamous cell skin cancer ; situ carcinoma cervix , treat curatively without evidence recurrence least 3 year prior study entry ; solid tumor treat curatively , without evidence recurrence least 3 year prior study entry . 8 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 9 . History thromboembolic cerebrovascular event within last 6 month Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BRAF mutant ,</keyword>
	<keyword>BRAF mutate ,</keyword>
	<keyword>melanoma ,</keyword>
	<keyword>metastatic ,</keyword>
	<keyword>advanced ,</keyword>
	<keyword>RAF kinase inhibitor</keyword>
	<keyword>BRAF V600 mutation</keyword>
</DOC>